MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Lipocine Company Profile (NASDAQ:LPCN)

Consensus Ratings for Lipocine (NASDAQ:LPCN) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.75 (615.46% upside)

Analysts' Ratings History for Lipocine (NASDAQ:LPCN)
Show:
DateFirmActionRatingPrice TargetActions
3/15/2016Canaccord GenuityReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2015Roth CapitalInitiated CoverageBuy$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2015Evercore ISIInitiated CoverageBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/16/2015Evercore Partners Inc.Initiated CoverageBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for Lipocine (NASDAQ:LPCN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/9/2016Q1($0.33)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q3($0.35)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015($0.20)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.35)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015($0.35)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.58)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014($0.42)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014($0.35)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Lipocine (NASDAQ:LPCN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.34)($0.19)($0.27)
Q2 20162($0.38)($0.34)($0.36)
Q3 20162($0.34)($0.30)($0.32)
Q4 20162($0.49)($0.35)($0.42)
(Data provided by Zacks Investment Research)
Dividend History for Lipocine (NASDAQ:LPCN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Lipocine (NASDAQ:LPCN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/30/2015John W HiguchiDirectorBuy5,000$12.68$63,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015Mahesh V. PatelCEOBuy4,000$11.84$47,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Mahesh V PatelCEOBuy2,000$5.10$10,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Mahesh V PatelCEOBuy2,000$5.45$10,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Richard Dana OnoDirectorBuy4,000$5.14$20,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Mahesh V PatelCEOBuy2,000$5.06$10,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Mahesh V PatelCEOBuy2,000$5.05$10,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Stephen A HillDirectorBuy4,000$4.95$19,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Lipocine (NASDAQ:LPCN)
DateHeadline
07/01/16 04:00 PMEQUITY ALERT: Rosen Law Firm Files Securities Class Action Against Lipocine Inc. - LPCN - [Business Wire] - Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Lipocine Inc. securities from June 30, 2015 through June 28, 2016, inclusive .
07/01/16 07:49 AMEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Lipocine, Inc. – LPCN
06/30/16 05:17 PMEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Lipocine, Inc. - LPCN
06/30/16 01:34 PMDeconstructing the Lipocine Inc (LPCN) Complete Response Letter -
06/30/16 01:30 PMLPCN: FDA Issues CRL for Tlando -
06/30/16 07:55 AMLipocine : Glancy Prongay & Murray Commences Investigation on Behalf of Lipocine Inc. Investors
06/30/16 07:55 AMLipocine says US FDA does not approve its testosterone product
06/30/16 07:55 AMLipocine Crashes After Receiving CRL From the FDA
06/30/16 07:55 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lipocine, Inc. - LPCN
06/30/16 07:55 AMLipocine Inc (LPCN) Sees Significant Increase in Short Interest
06/30/16 07:55 AMDeconstructing the Lipocine Inc (NASDAQ:LPCN) Complete Response Letter
06/29/16 04:54 PMLipocine Inc. (NASDAQ:LPCN) Fell -12.28% in Afterhours: Ensco plc (NYSE:ESV), Shopify Inc. (NYSE:SHOP), Trina ... - KC Register
06/29/16 04:54 PMShares Entering Oversold Area: Lipocine Inc. (NASDAQ:LPCN) - Press Telegraph
06/29/16 04:54 PMWatching Stock Volatility for: Lipocine Inc. (NASDAQ:LPCN) - Engelwood Daily
06/29/16 04:54 PMLipocine Inc. (NASDAQ:LPCN) Company Rating and Target Watch - Telanagana Press
06/29/16 04:54 PMShareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Lipocine, Inc. (LPCN) - PR Newswire (press release)
06/29/16 03:59 PMIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation Of Lipocine, Inc. And Advises Investors With Losses to Contact the Firm - [Business Wire] - Lundin Law PC announces it is investigating claims against Lipocine, Inc. concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Lipocine were false and misleading and/or failed to disclose material information regarding the Company’s financial performance.
06/29/16 12:58 PM7 Biggest Mid-Day Losers For Wednesday -   Galena Biopharma Inc (NASDAQ: GALE) shares dropped 85 percent to $0.310 after the company reported the discontinuation of Phase 3 PRESENT clinical trial due to futility of study. Lipocine Inc (NASDAQ: LPCN) shares tumbled 51.8 percent to $3.03 following announcement of a Complete Response Letter from the FDA. The response letter noted deficiencies in dosing algorithm on label. Esperion Therapeutics Inc (NASDAQ: ESPR) shares fell 38.2 percent to $9.99 after failing to ...Full story available on Benzinga.com
06/29/16 07:51 AMManufacturing Stocks: Losers, Gainers Summary
06/29/16 07:51 AMLipocine : Added to Russell 3000 and Russell Global Indexes
06/29/16 07:51 AMLipocine Gets CRL From FDA For LPCN 1021 - Quick Facts
06/29/16 07:51 AMLipocine (LPCN) Receives FDA CRL for LPCN 1021
06/29/16 07:51 AMLipocine Receives Complete Response Letter (CRL) for LPCN 1021 From U.S. Food and Drug Administration
06/29/16 07:05 AMLipocine says FDA does not approve its testosterone drug - [Reuters] - Lipocine Inc said its oral testosterone replacement product did not get the approval in the United States, sending the drugmaker's shares down 52 pct in premarket trading. LPCN 1021, Lipocine's most advanced drug, is intended to treat adult males who suffer from deficiency or absence of testosterone that could lead to a loss of libido, decreased muscle mass, fatigue and depression. The U.S. Food and Drug Administration's decision was conveyed via a complete response letter, which said the "application cannot be approved in its present form".
06/28/16 04:56 PMCheck on Share Volatility: Lipocine Inc. (NASDAQ:LPCN) - Engelwood Daily
06/27/16 04:55 PMShare Update and Earnings Review for Lipocine Inc. (NASDAQ:LPCN) - Press Telegraph
06/27/16 04:55 PMNext Weeks Broker Price Targets For Lipocine Inc (LPCN) - Fiscal Standard
06/27/16 04:55 PMTraders Observable Stocks: Egalet Corporation (NASDAQ:EGLT) , Lipocine Inc. (NASDAQ:LPCN) - Street Updates
06/27/16 07:01 AMLIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/27/16 07:00 AMLipocine Added to Russell 3000 and Russell Global Indexes - [GlobeNewswire] - SALT LAKE CITY, June 27, 2016-- Lipocine Inc., a specialty pharmaceutical company, today announced that it has been added to the Russell 3000 ® and Russell Global ® Indexes, effective after the U.S. market ...
06/26/16 04:19 PMOption Market: Lipocine Inc. (NASDAQ:LPCN) Risk Hits Extreme High - CML News
06/24/16 04:57 PMLipocine Inc. (NASDAQ:LPCN) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 07:37 AMCovering the Bases on Lipocine Inc. (NASDAQ:LPCN): Where is the Stock Going? - Press Telegraph
06/23/16 07:44 AMManufacturing Stocks Daily Advances, Losers
06/18/16 04:26 PMLPCN-1021
06/17/16 04:50 PMSlingshot Insights' Expert Conference Call On Lipocine - Benzinga
06/17/16 02:52 PMSlingshot Insights' Expert Conference Call On Lipocine - Lipocine Inc (NASDAQ: LPCN)’s LPCN-1021’s PDUFA date is coming up on June 28. Given the major potential near-term catalyst, Slingshot Insights recently conducted an expert conference call with a professor, researcher and a clinical director from the Department of Medicine at Johns Hopkins University on June 9 to allow investors the chance to ask questions about the oral male hypogonadism drug. Here are some highlights from the call. In terms of market penetration, the expert told callers, “There is a need for an oral medication. I think it’s going to take a big chunk of ...Full story available on Benzinga.com
06/15/16 07:01 AMLIPOCINE INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/13/16 07:55 AMTop Manufacturing Stocks Review
06/08/16 03:31 PMHere's Why You Should Watch For Movement In Lipocine Tomorrow -
06/06/16 01:31 PMLipocine, Inc. :LPCN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/06/16 08:43 AMStock Review and Earnings Check on Lipocine Inc. (NASDAQ:LPCN) - HNN
06/03/16 07:47 AMShare Rating Focus on Lipocine Inc. (NASDAQ:LPCN) - HNN - Share Rating Focus on Lipocine Inc. (NASDAQ:LPCN)HNNPresently, Wall Street analysts have given a consensus stock rating of 1 on shares of Lipocine Inc. (NASDAQ:LPCN). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus number is ...and more »
06/02/16 05:19 PMAdobe Systems Incorporated (NASDAQ:ADBE) Up -0.48% premarket: Lipocine Inc. (NASDAQ:LPCN), Analog Devices ... - KC Register - Adobe Systems Incorporated (NASDAQ:ADBE) Up -0.48% premarket: Lipocine Inc. (NASDAQ:LPCN), Analog Devices ...KC RegisterLipocine Inc. (NASDAQ:LPCN) traded 208434 shares and its share price decreased -2.63% to close at $8.51. Company has 15.94% insider ownership. Lipocine Inc. (NASDAQ:LPCN) quarterly performance is -18.02% while its year to date (YTD) performance ...and more »
06/02/16 07:51 AMTarget Price and Stock Performance Rundown for Lipocine Inc. (NASDAQ:LPCN) - HNN - Target Price and Stock Performance Rundown for Lipocine Inc. (NASDAQ:LPCN)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Lipocine Inc. (NASDAQ:LPCN) shares ...and more »
05/30/16 11:35 AMLipocine Incorporated (NASDAQ:LPCN) Short Interest Increased By 6.12% - HNN - Lipocine Incorporated (NASDAQ:LPCN) Short Interest Increased By 6.12%HNNThe short interest to Lipocine Incorporated's float is 8.83%. The stock increased 0.33% or $0.03 on May 27, hitting $9.07. About 244,069 shares traded hands or 14.23% up from the average. Lipocine Inc (NASDAQ:LPCN) has declined 17.77% since October ...and more »
05/27/16 11:01 AMStock Rating Review for Lipocine Inc. (NASDAQ:LPCN) - Wall Street Hints and News - Stock Rating Review for Lipocine Inc. (NASDAQ:LPCN)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of Lipocine Inc. (NASDAQ:LPCN). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating is compiled ...and more »
05/27/16 11:01 AMLipocine Inc (LPCN) Updated Broker Price Targets - Share Trading News - Lipocine Inc (LPCN) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Lipocine Inc (LPCN). The latest reports which are currently in issue on Friday 27th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...
05/19/16 01:37 PMLipocine Inc. (NASDAQ:LPCN) One-Year Price Projection At $23.5 - Investor Newswire - Lipocine Inc. (NASDAQ:LPCN) One-Year Price Projection At $23.5Investor NewswireSell-side analysts are certain on the prospect of Lipocine Inc. (NASDAQ:LPCN) stock. As of 2016-05-17, the stock ABR stands at 1. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in such stocks ...and more »
05/19/16 01:37 PMShare Performance and Target Price Review for Lipocine Inc. (NASDAQ:LPCN) - Wall Street Hints and News - Share Performance and Target Price Review for Lipocine Inc. (NASDAQ:LPCN)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Lipocine Inc. (NASDAQ:LPCN ...and more »
About Lipocine

Lipocine logoLipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: LPCN
  • CUSIP:
Key Metrics:
  • Previous Close: $3.04
  • 50 Day Moving Average: $7.73
  • 200 Day Moving Average: $9.85
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $55.50M
  • Current Quarter EPS Consensus Estimate: $-1.33 EPS
Additional Links:
Lipocine (NASDAQ:LPCN) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha